ArticleCureus2025
Prostatic Solitary Fibrous Tumor With Pulmonary Metastases: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary fibrous tumors (SFT) are rare intermediate-grade mesenchymal neoplasms with unpredictable clinical courses, including the potential for late metastases. While most commonly arising in the pleura, extrapleural SFTs have been described. However, SFTs originating from the prostate are exceptionally rare, and their potential for metastatic progression remains largely unknown. A 59-year-old male presented with lower urinary tract symptoms and underwent Holmium laser enucleation of the prostate (HoLEP) after unsuccessful medical therapy. Histopathological examination revealed spindle-shaped neoplastic cells that were positive for cluster of differentiation 34 (CD34) and signal transducer and activator of transcription 6 (STAT6), confirming SFT. Radical prostatectomy was subsequently performed with negative surgical margins. Twenty-three months later, thoracic imaging detected two pulmonary nodules. Fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) and percutaneous biopsy confirmed metastatic SFT. Both lung lesions were surgically resected, followed by adjuvant chemotherapy with ifosfamide and doxorubicin. The patient has remained in remission for 18 months. This case emphasizes that even histologically benign-appearing prostatic SFTs can demonstrate malignant potential. It also underscores the necessity of long-term surveillance and contributes to the literature by reporting the first known case of a metastatic SFT originating from the prostate gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.